Sai Parenterals Ltd
Incorporated in 2001, Sai Parenteral's Ltd. is a diversified pharmaceutical formulations company with expertise in research, development, and manufacturing.[1]
- Market Cap ₹ 2,115 Cr.
- Current Price ₹ 478
- High / Low ₹ 706 / 400
- Stock P/E 85.2
- Book Value ₹
- Dividend Yield 0.00 %
- ROCE 7.03 %
- ROE 5.80 %
- Face Value ₹ 5.00
Pros
Cons
- Company has a low return on equity of 7.99% over last 3 years.
- Company has high debtors of 183 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of Nifty IPO BSE Healthcare BSE IPO
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| 97 | 114 | 124 | 162 | |
| 79 | 92 | 97 | 134 | |
| Operating Profit | 18 | 21 | 27 | 28 |
| OPM % | 18% | 19% | 22% | 18% |
| 0 | 1 | 0 | 5 | |
| Interest | 5 | 6 | 7 | 9 |
| Depreciation | 6 | 6 | 5 | 6 |
| Profit before tax | 7 | 10 | 14 | 19 |
| Tax % | 37% | 30% | 28% | 11% |
| 5 | 7 | 10 | 17 | |
| EPS in Rs | 3.22 | 2.70 | 3.86 | 3.80 |
| Dividend Payout % | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 19% |
| TTM: | 31% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 55% |
| TTM: | 63% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 8% |
| Last Year: | 6% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Equity Capital | 7 | 13 | 13 | 22 |
| Reserves | 24 | 65 | 78 | 465 |
| 69 | 71 | 72 | 133 | |
| 34 | 45 | 52 | 184 | |
| Total Liabilities | 134 | 194 | 215 | 804 |
| 44 | 41 | 40 | 43 | |
| CWIP | 2 | 0 | 0 | 1 |
| Investments | 0 | 28 | 28 | 158 |
| 88 | 124 | 146 | 602 | |
| Total Assets | 134 | 194 | 215 | 804 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| -21 | -4 | 19 | 112 | |
| -17 | -32 | -13 | -136 | |
| 30 | 36 | -6 | 433 | |
| Net Cash Flow | -8 | -1 | -0 | 409 |
| Free Cash Flow | -38 | -7 | 14 | 105 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | -103% | -6% | 77% | 413% |
Ratios
Standalone / View Consolidated
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Debtor Days | 231 | 272 | 254 | 183 |
| Inventory Days | 83 | 97 | 130 | 208 |
| Days Payable | 140 | 156 | 160 | 89 |
| Cash Conversion Cycle | 174 | 213 | 224 | 302 |
| Working Capital Days | 27 | 70 | 53 | -216 |
| ROCE % | 13% | 14% | 7% |
Insights
In beta| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Group-wide capacity utilisation % |
|
|||
| CDMO revenue YoY growth % |
||||
| Cumulative product registrations in regulated markets count |
||||
| Dossiers approved/filed in the year count |
||||
| Dossiers developed in-house by R&D subsidiary (cumulative) count |
||||
| Dossiers under development (pipeline) count |
||||
| Installed manufacturing capacity - Revat Laboratories (Ongole) million units |
||||
| Installed manufacturing capacity - Unit I (Injectables) million units |
||||
| Installed manufacturing capacity - Unit III (General Oral Dosage Forms) million units |
||||
| Installed manufacturing capacity - Unit IV (Cephalosporin Oral Dosage Forms and Injectables) million units |
||||
| Number of complex products in portfolio count |
||||
| Pharmacy reach in Australia via long-term supply networks count |
||||
| Share of consolidated revenue from long-term supply contracts in regulated markets % |
||||
| TGA-Australia product registrations count |
||||
Extracted by Screener AI
Documents
Announcements
-
Board Meeting Intimation for Declaration Of Unaudited Financial Results Of The Quarter And Half Year Ended 30Th September, 2026.
- Board meeting on 1 November 2026 to consider Q2/H1 FY2026-27 results and review reports.
- Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
- Sai Parenterals acquired 60% of Prathyak Laboratories for Rs. 15 crore on 05 Oct 2026.
-
Announcement under Regulation 30 (LODR)-Monitoring Agency Report
- Monitoring agency report for quarter ended 30 June 2026 noted IPO proceeds deviations up to 10% and delayed capex.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
- Intimation of Schedule of Analyst / Institutional Investor meetings under Regulation 30 (read with Para A of Part A of Schedule III) of SEBI (LODR) …
Concalls
-
Aug 2026Transcript PPT REC
-
May 2026Transcript PPT
Business Profile[1][2]
Sai Parenteral is a diversified pharmaceutical formulations company engaged in R&D, manufacturing, and commercialization of products across both domestic and international markets. Over time, the company has evolved from being a parenteral-focused player into a full-fledged diversified formulations platform, significantly reducing its dependency on injectables in the process.